Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pozdeutinurad - Arthrosi Therapeutics Australia

Next Previous
Drug Profile

Pozdeutinurad - Arthrosi Therapeutics Australia

Alternative Names: AR-882; POZD

Latest Information Update: 05 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arthrosi Therapeutics Australia
  • Developer Arthrosi Therapeutics Australia; Guangzhou Ruianbo Pharmaceutical Technology; Swedish Orphan Biovitrum
  • Class Antigouts; Small molecules; Uricosurics
  • Mechanism of Action SLC22A12 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gout
  • Phase II/III Hyperuricaemia

Most Recent Events

  • 21 May 2026 Efficacy and safety data from a phase-III REDUCE 2 trial in Goat released by Swedish Orphan Biovitrum
  • 10 Apr 2026 Arthrosi Therapeutics completes the phase-III REDUCE 2 trial in Gout in the US, Australia, Hong Kong, New Zealand, Taiwan (PO) (NCT06439602)
  • 09 Feb 2026 Arthrosi Therapeutics has been acquired and merged into Swedish Orphan Biovitrum

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top